tbuckley/cabot-search huggingface dataset:
Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.
Authors: Robert Z. Orlowski, Bercedis L. Peterson, Ben Sanford, Asher A. Chanan-Khan, Lee M. Zehngebot, Peter R. Watson, Michael A. Caligiuri, Richard A. Larson
Journal: Blood (2006)
Gene expression profiling and activation status of signaling pathways in pediatric gliomas and correlation with clinical outcome
Authors: Halldora K. Thorarinsdottir, Mariarita Santi, Tobey J. MacDonald
Journal: Cancer Research (2006)

1837   Background: Gliomas are the most common central nervous system (CNS) tumor during childhood. About 30% of these tumors are malignant and have a dismal prognosis with only third of patients surviving after aggressive treatment. Very little is known about the molecular basis for malignant progression of pediatric gliomas, which might facilitate targeted therapeutic interventions in the future. The objective of this study was to investigate whether pediatric gliomas that overexpress either epidermal-growth-factor receptor (EGFR) or platelet-derived growth-factor receptor beta (PDGFRβ), as well as their active signaling pathways, were more likely to exhibit aggressive behavior and be associated with worse clinical grade (WHO I-IV) and outcome, with the goal of identifying the most suitable targets for future therapeutic interventions. Methods: High throughput tissue microarrays (TMA) were prepared from tumors from 88 patients seen at CNMC from 1980 to 2004 with a new diagnosis of glioma (22 WHO grade III-IV (HGG), 66 WHO grade I-II (LGG)). Immunohistochemistry was applied to assess the expression levels of phosphorylated-EGFR (p-EGFR), total-EGFR, PDGFRβ, p-AKT, p-MAPK, and p-mTOR. Expression of the targets was evaluated by 3 investigators separately and correlated with clinical data including progression free survival (PFS), overall survival (OS), tumor grade, dissemination, proliferation index and age. Results: 32 out of 88 patients had tumor progression (15 LGG and 17 HGG) median 10 months (range 0-87 months) after diagnosis and 12 of these died (11 HGG, 1 LGG) median 14 months (range 0-42 months) after diagnosis. High expression of EGFR, p-EGFR and PDGFRβ was seen in 78.9%, 47.4% and 78.9% of HGG and 87.3%, 52.6% and 41.7% of LGG respectively. Forty patients with high expression of PDGFRβ had significantly worse OS compared to that of 39 patients with low expression (5 year OS 69.0% and 96.9% respectively, p=0.0084). High expression of EGFR, p-EGFR and their signaling pathways was not associated with worse PFS or OS. High proliferation index (MIB>10%) and disseminated disease at diagnosis correlated with worse clinical outcome for HGG patients. Conclusion: High expression of PDGFRβ was significantly associated with lower overall survival in 88 pediatric glioma patients, primarily due to worse OS of patients with malignant histology and high PDGFRβ expression compared to patients with malignant histology and low PDGFRβ expression. Our results suggest that an approach to stratify pediatric glioma patients upfront for targeted PDGFR-kinase inhibitor therapy may be warranted. Furthermore, high expression of EGFR and its active signaling pathways was not shown to be a significant biological marker for predicting adverse clinical outcome in either low-grade or high-grade pediatric gliomas.
PTPS-19SURVIVAL AND PROGNOSTIC FACTORS IN CHILDREN WITH POSTERIOR FOSSA TUMORS ADMITTED AT THE PHILIPPINE CHILDREN'S MEDICAL CENTER FROM 2004 TO 2013
Authors: Alpha Mallillin, Martha Lu-Bolanos, Jose Francisco Aguilar
Journal: Neuro-Oncology (2015)

BACKGROUND: Childhood brain tumors are the most common solid neoplasm and the leading cause of cancer-related morbidity and mortality in children. OBJECTIVES: To determine which patient and tumor characteristics are predictive of good outcome in patients with posterior fossa tumors. DESIGN: Analytical retrospective, cross sectional study. SETTING: Tertiary level hospital. PATIENTS: Total of 85 charts of children with posterior fossa tumors admitted at PCMC from 2004 to 2013 were reviewed. MAIN OUTCOME MEASURE(S): Patient and tumor characteristics were determined and analyzed using univariate analysis. Age, extent of tumor resection, and tumor histology were analyzed if predictive of poor outcome. One-year and 3-year overall survival probability were analyzed using the Kaplan-Meier estimation method. Mantel-Cox Log-Rank Overall Comparisons was used to identify prognostic variables for over-all survival. RESULTS: Medulloblastoma is the most common tumor at 62%, pilocytic astrocytoma 23% and ependymoma 11%. Majority belongs to the 36months and older age group with male predominance at 1.36:1. Most common signs and symptoms were headache, vomiting and ataxia. The 1-year and 3-year overall survival probability are 61% and 41%, respectively. Univariate analysis showed that clinical outcome was significantly correlated with gender (female associated with good clinical outcome, p = 0.022) and histologic tumor types (medulloblastoma associated with poor outcome; pilocytic astrocytoma with good outcome, p = 0.012). Gender and histologic tumor types and brainstem involvement were identified as significant factors for 1- and 3-year overall survival (p = 0.049, p = 0.008, and p = 0.029). CONCLUSION: Gender and histologic type of tumors are significant prognostic factors for both the clinical outcome and overall 1-year and 3-year survival probability. Brainstem involvement is a significant prognostic variable for overall survival. One- and three-year overall survival rates are 61 % and 41%, respectively. The need to formulate an institutional tumor guideline to ensure standard treatment and follow-up of these patients are necessary.
Potent Phosphorodiester-Based DNA Immunomodulators (dSLIM) Exhibit Enhanced Safety Compared to Phosphorothioate-Based Oligonucleotides.
Authors: Manuel Schmidt, Javier de Christobal, Nicole Hagner, Astrid Sander, Alberto Marco, Sven A. Koenig-Merediz, Burghardt Wittig
Journal: Blood (2005)
In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.
Authors: Thorsten Zenz, Matthias Volden, Theresa Mast, Antonio Sarno, Dirk Winkler, Andrea Schnaiter, Andreas Bühler, Christian Klein, Pablo Umana, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2009)
Chimerism Analyses in Stem Cell Recipients with Non Hodgkin Lymphoma
Authors: Gabriela Bernadeta Iwanski, Sunday Ocheni, Maite Hartwig, Boris Fehse, Tatjana Zabelina, Alexander Muth, Silke Zeschke, Friederike Lehmann, Axel R. Zander, Nicolaus Kroeger, Ulrike Bacher
Journal: Blood (2008)
Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience
Authors: Elza Lomaia, Ekaterina Romanova, Larisa Girshova, Yulia Alexeeva, Eugenia Sbityakova, Elena Goriunova, Vladimir Strugov, Natalia Lazorko, Nadia Siordia, Diana Mescheryakova, Tatiana Silina, Dmitry Motorin, Andrey Zaritskey
Journal: Blood (2013)
Correction: Identification and treatment of the <i>Staphylococcus aureus</i> reservoir in vivo
Authors: Bas G.J. Surewaard, Justin F. Deniset, Franz J. Zemp, Matthias Amrein, Michael Otto, John Conly, Abdelwahab Omri, Robin M. Yates, Paul Kubes
Journal: The Journal of Experimental Medicine (2016)

Vol. 213, No. 7, June 27, 2016. Pages [1141–1151][1].

The authors regret that in their original paper, the y axis labels in Fig. 5 h were reversed. The corrected figure appears below. The online HTML and PDF versions of this article have been corrected. The error only remains in the print version
T-bet Down-Modulation in Tolerized Th1 Effector CD4 Cells Confers a TCR-Distal Signaling Defect That Selectively Impairs IFN- γ Expression.
Authors: Meixiao Long, Aaron M. Slaiby, Adam T. Hagymasi, Marianne A. Mihalyo, Alexander C. Lichtler, Steven L. Reiner, Adam J. Adler
Journal: Blood (2005)
AB0350 Rituximab Seems Outstanding Biological Option in Late Onset Rheumatoid Arthritis: Hur-Bio Real Life Results
Authors: L. Kilic, A. Erden, A. Sari, B. Armagan, O. Karadag, A. Akdogan, S. Apras Bilgen, S. Kiraz, I. Ertenli, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) can be categorized into late-onset RA and young-onset RA. Age at disease onset may implicate on disease activity, disease severity, comorbidity and also may have an impact on physicians9 treatment choices. <h3>Objectives</h3> The aim of this study was to assess clinical and laboratory features, disease activity, response, and biological treatment choices according to late-onset RA and young-onset RA patients. <h3>Methods</h3> Hacettepe University Biologic Registry (HUR-BIO) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic and clinical data and disease activity parameters. A total of 1087 (79.4% female) patients from the HURBIO registry were analyzed. Patients were categorized into two groups: young-onset RA (n=990, &lt;60 years of age) and late-onset RA (n=97, ≥60 years of age) at disease onset. DAS-28 remission (&lt;2.6) and low disease activity (&lt;3.2) were assessed at last outpatient visit. <h3>Results</h3> The female gender was similar in both age group (77.3% vs. 79.6%, p&gt;0.05). Mean age of patients were 71.4±6.0 years in late-onset RA and 51.6±11.7 years in young-onset RA group. The median age at diagnosis of patients were 64 (range 60–85) years in late-onset RA and 40 (range17–59) years in young-onset RA patients. Mean disease duration between diagnosis of RA and first biologic therapy was longer in young-onset RA patients [7.7±7.3 vs. 2.7±2.6 years, p&lt;0.001], but mean biologic duration was similar in both groups [29.9±27.5 vs. 38.4±37.1 months, p&gt;0.05]. Rheumatoid factor and anti-citrullinated peptides positivity in late-onset RA and young-onset RA patients were; 56.2% vs. 63.8% (p&gt;0.05) and 45.9% vs. 63.2%, p=0.008, respectively. At the baseline level, anti-TNF (61 (61.9%) vs. 827 (73.6%), p=0.014) drugs were less frequently used in late-onset RA, rituximab (21 (21.6%) vs 111 (11.3%), p=0.003) was more frequently used in late-onset RA, and abatacept (16 (16,5%) vs. 148 (15,1%), p&gt;0.05) was used similar in both group. Change in DAS-28 score was similar [1.55±1.14 vs. 1.79±1.45 (p&gt;0.05)], in late-onset RA and young-onset RA patients. Remission (29.5% vs. 38.6%, p&gt;0.05) and low disease activity (52.5% vs. 55.4%, p&gt;0.05) were similar in late-onset RA and young-onset RA patients. Biological switch ratio was significantly lower in late-onset RA group, 18.6% vs. 35.2%, p&lt;0.001. <h3>Conclusions</h3> Age may influence the clinician choice based on the efficacy and safety profile. Biologic drugs are effective in late-onset RA, as well. Rituximab was relatively more preferred in late-onset RA patients; may be related with administration of every 6 months and safety profile in malignancy risk. Patient and physician opinion on these choices should be evaluated in further studies. <h3>Disclosure of Interest</h3> None declared
Plerixafor On Demand Associated With Chemotherapy and G-CSF: Interim Analysis Of a Prospective Study Shows Significant Improvement In PBSC Mobilization and Harvest With No Increase In Costs
Authors: Giuseppe Milone, Massimo Martino, Potito R Scalzulli, Andrea Spadaro, Valentina Di Martina, Elena Schinocca, Eleonora Spina, Annalia Di Marco, Alessandra Cupri, Giovanni Tripepi, Salvatore Leotta
Journal: Blood (2013)
Autophagy and Apoptosis Are Induced Simultaneously in Leukemia Cells by Vitamin K2.
Authors: Keisuke Miyazawa, Tomohisa Yokoyama, Juri Toyotake, Akihiko Gotoh, Munekazu Naito, Masahiro Ito, Akira Yuo, Seiji Kondo, Kazuma Ohyashiki
Journal: Blood (2006)
Activation of Endothelial Cells (EC) Leads to Release of Inhibitory Endothelial Microparticles (EMP) and Decreased Intracellular ADAMTS13 Activity.
Authors: Joaquin J. Jimenez, Wenche Jy, Lucia M. Mauro, Katherine M. Lens, Noor Daghistani, Hannah J. Dodson, Lawrence L. Horstman, Yeon-Soong Ahn
Journal: Blood (2006)
OC-087 Frequency of Health Risk Behaviours in Young People With Inflammatory Bowel Disease
Authors: AJ Brooks, G Rowse, EJ Peach, A Ryder, P Narula, BM Corfe, P Norman, AJ Lobo
Journal: Gut (2016)

<h3>Introduction</h3> Young people (YP) with any chronic illness are 3 times more likely to engage in health risk behaviours (HRBs) than healthy peers.<sup>1</sup> HRBs are a leading cause of morbidity and mortality, and are associated with poor self-management skills in adulthood. The aim of this study was to investigate the frequency of HRBs in YP with inflammatory bowel disease (IBD). <h3>Methods</h3> YP aged 16–22 years with a confirmed diagnosis of IBD were recruited from a paediatric and adult IBD centre. Participants completed The Youth Risk Behaviour Survey (YRBS)–adapted, with demographic, disease and treatment-related data. <h3>Results</h3> 121 patients were studied (75 (62%) CD, 39 (32%) UC, 7 (6%) IBDU), median age 19 years (range 16–22 years). Eight HRBs were identified including; 1) daily smoking in 15/117 (13%); 2) current alcohol misuse in 58/117 (49%); 3) current cannabis use in 12/117 (10%); 4) current use of other illegal drug in 20/121 (17%) with 39/118 (33%) offered, given or sold illegal drugs in the preceding 12 months; 5) previous sexual activity in 71/118 (59%), of whom 25/71 (35%) ≥4 previous sexual partners and 40/71 (56%) without condom use; 6) violent acts with physical fights in 8/118 (7%) and forced sexual intercourse in 5/118 (4%); 7) drink driving in 6/119 (5%) and texting whilst driving 14/118 (12%); 8) suicidal ideation in 9/118 (9%) and attempted suicide in 2/118 (2%). Of these HRBs, males were significantly more likely to participate in current illegal drug use (14/60 vs. 6/61) (<i>P</i> = 0.02) and drink driving (6/59 vs. 0/59) (<i>P</i> = 0.03). YP aged ≥19-22years were significantly more likely to participate in current illegal drug use (15/65 vs 5/56) (<i>P</i> = 0.05), ≥4 sexual partners (21/45 vs. 4/26) (<i>P</i> = 0.01), without condom use (31/45 vs. 9/26) (<i>P</i> = 0.007) and to text whilst driving (13/64 vs. 1/54) (<i>P</i> = 0.003) compared to YP aged 16- &lt;19 years. <h3>Conclusion</h3> In YP with IBD high levels of alcohol misuse and illegal drug use are observed compared to other chronic health conditions and healthy peers.<sup>1</sup> Clinician awareness of HRBs is vital for both paediatric and adult healthcare providers, with specific YP training for discussion of HRBs needed. Research is needed to understand factors which predispose YP with IBD to participate in HRBs, the impact on disease severity, and possible related outcomes such as psychological distress/morbidity that may have significant long-term health economic implications. <h3>Reference</h3> 1 Suris JC, <i>et al. Paediatrics</i> 2008; <b>122</b>(5):e113–elll8. <h3>Disclosure of Interest</h3> None Declared
A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters
Authors: Feras Alfraih, John Kuruvilla, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis Dong Hwan Kim, Matthew D. Seftel, Jieun Uhm, David Loach, Eshetu G Atenafu, Jeffrey H. Lipton, Hans A. Messner
Journal: Blood (2014)
SAT0577 Patient-Reported DAS28 in Rheumatoid Arthritis: Its Reliability in A Longitudinal Study
Authors: E.Y. Tang, C. Chattopadhyay, K.L. Hyrich
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There have been increasing studies focusing on patient derived joint counts in RA. Patient self-reported DAS28 with training has not been observed longitudinally in the UK. <h3>Objectives</h3> The aims of the study were to (1) evaluate the reliability of patient self-assessment of DAS28 compared to physician DAS28; (2) determine whether the agreement between patient-reported and physician-reported DAS28 improves over time with training. <h3>Methods</h3> This was a longitudinal study with a total of 3 study visits 6 weeks apart carried out at two hospitals sites in the United Kingdom. All 42 patients had training on joint count self-assessment. A single physician performed joints assessment on patients independently blinded to the patients9 data. Correlations between patient and physician measurements were analysed using Spearman correlation coefficient whereas agreement between patient and physician was analysed with Bland-Altman plots. <h3>Results</h3> There was very strong correlation between patient and physician DAS28-CRP, DAS28-ESR, TJC and SJC (r &gt;0.80). The limits of agreement of DAS28 were consistent (range -0.65 to 0.69) but exceeded the set difference of 0.6, although with very small mean difference. <h3>Conclusions</h3> Overall, it is reasonable to conclude that there were good agreement of tender and swollen joint assessments between patient and physician. Patient training has positive effects in increasing the reliability of patient self-assessment of joint counts. Our study showed patient-reported DAS28 was not exactly same as physician-reported DAS28, although DAS28, TJC and SJC from both patient and physician were all very strongly correlated. Patient-reported joint counts were shown to have a strong predictive value and therefore could be incorporated in clinical practice. Patient DAS28 and physician DAS28 could act synergistically to reach a consensus evaluation of RA in order to achieve treatment optimisation. <h3>Acknowledgement</h3> Dr Jamie Sergeant, a Lecturer in Statistics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, the University of Manchester. <h3>Disclosure of Interest</h3> None declared
Development and Initial Validation of the Risk Analysis Index for Measuring Frailty in Surgical Populations
Authors: Daniel E. Hall, Shipra Arya, Kendra K. Schmid, Casey Blaser, Mark A. Carlson, Travis L. Bailey, Georgia Purviance, Tammy Bockman, Thomas G. Lynch, Jason Johanning
Journal: JAMA Surgery (2016)

Growing consensus suggests that frailty-associated risks should inform shared surgical decision making. However, it is not clear how best to screen for frailty in preoperative surgical populations.To develop and validate the Risk Analysis Index (RAI), a 14-item instrument used to measure surgical frailty. It can be calculated prospectively (RAI-C), using a clinical questionnaire, or retrospectively (RAI-A), using variables from the surgical quality improvement databases (Veterans Affairs or American College of Surgeons National Surgical Quality Improvement Projects).Single-site, prospective cohort from July 2011 to September 2015 at the Veterans Affairs Nebraska-Western Iowa Heath Care System, a Level 1b Veterans Affairs Medical Center. The study included all patients presenting to the medical center for elective surgery.We assessed the RAI-C for all patients scheduled for surgery, linking these scores to administrative and quality improvement data to calculate the RAI-A and the modified Frailty Index.Receiver operator characteristics and C statistics for each measure predicting postoperative mortality and morbidity.Of the participants, the mean (SD) age was 60.7 (13.9) years and 249 participants (3.6%) were women. We assessed the RAI-C 10 698 times, from which we linked 6856 unique patients to mortality data. The C statistic predicting 180-day mortality for the RAI-C was 0.772. Of these 6856 unique patients, we linked 2785 to local Veterans Affairs Surgeons National Surgical Quality Improvement Projects data and calculated the C statistic for both the RAI-A (0.823) and RAI-C (0.824), along with the correlation between the 2 scores (r = 0.478; P < .001). Of these 2785 patients, there were sufficient data to calculate the modified Frailty Index for 1021, in which the C statistics were 0.865 (RAI-A), 0.797 (RAI-C), and 0.811 (modified Frailty Index). The correlation between the RAI-A and RAI-C was 0.547, and the correlations of the modified Frailty Index to the RAI-A and RAI-C were 0.301 and 0.269, respectively (all P < .001). A cutoff of RAI-C of at least 21 classified 18.3% patients as "frail" with a sensitivity of 0.50 and specificity of 0.82, whereas the RAI-A was less sensitive (0.25) and more specific (0.97), classifying only 3.7% as "frail."The RAI-C and RAI-A represent effective tools for measuring frailty in surgical populations with predictive ability on par with other frailty tools. Moderate correlation between the measures suggests convergent validity. The RAI-C offers the advantage of prospective, preoperative assessment that is proved feasible for large-scale screening in clinical practice. However, further efforts should be directed at determining the optimal components of preoperative frailty assessment.
The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin
Authors: Kelly Zullo, Yige Guo, Laurence Cooke, Xavier Jirau Serrano, Michael Mangone, Luigi Scotto, Jennifer E. Amengual, Daruka Mahadevan, Owen A. O'Connor
Journal: Blood (2014)
Abstract 19900: Lack of Patient Understanding of Stroke Risk and Treatment Strategies in Those With Newly Diagnosed Atrial Fibrillation: A Concern and an Opportunity
Authors: Emily C O’Brien, Larry A Allen, Sunghee Kim, Peter Shrader, Bernard J Gersh, Gerald V Naccarelli, Gregg C Fonarow, Jonathan P Piccini, Eric D Peterson
Journal: Circulation (2016)

Introduction: Patient understanding of stroke risk and available therapies are key components of shared medical decision making and long-term medication adherence. Yet, relatively little is known r...
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative
Authors: Pascal Sati, Jiwon Oh, R. Todd Constable, Nikos Evangelou, Charles R. G. Guttmann, Roland G. Henry, Eric C. Klawiter, Caterina Mainero, Luca Massacesi, Henry McFarland, Flavia Nelson, Daniel Ontaneda, Alexander Rauscher, William D. Rooney, Amal P. R. Samaraweera, Russell T. Shinohara, Raymond A. Sobel, Andrew J. Solomon, Constantina A. Treaba, Jens Wuerfel, Robert Zivadinov, Nancy L. Sicotte, Daniel Pelletier, Daniel S. Reich
Journal: Nature Reviews Neurology (2016)

The central vein sign (CVS) has been proposed as a novel MRI biomarker to improve the accuracy and speed of multiple sclerosis (MS) diagnosis. This Consensus Statement from the NAIMS Cooperative provides a roadmap to help radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS. Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.
Development of a Novel Anti-Leukemia Gene Immunotherapy Using Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer.
Authors: Kozo Nagai, Hiroshi Fujiwara, Toshiki Ochi, Toshiaki Shirakata, Junichi Mineno, Kiyotaka Kuzushima, Masaki Yasukawa
Journal: Blood (2009)